GHULAM MURTAZA BAJWA: Open Payments
NPI 1073713814 · PARAMUS, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$979 in 70 payments from 10 companies in 2025. Trend: 2023 $1,491 · 2024 $1,073 · 2025 $979
Food & beverage: $979
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $235 |
| E.R. Squibb & Sons, L.L.C. | 15 | $169 |
| Lundbeck LLC | 14 | $162 |
| Otsuka America Pharmaceutical, Inc. | 5 | $100 |
| ABBVIE INC. | 5 | $76 |
| Teva Pharmaceuticals USA, Inc. | 4 | $70 |
| Vanda Pharmaceuticals Inc. | 4 | $60 |
| Janssen Pharmaceuticals, Inc | 3 | $46 |
| Supernus Pharmaceuticals, Inc. | 3 | $44 |
| Axsome Therapeutics, Inc. | 1 | $19 |
Products named: CAPLYTA, REXULTI, COBENFY, VRAYLAR, UZEDY, ABILIFY ASIMTUFII, HETLIOZ, INVEGA SUSTENNA.
Industry payments across NJ — which companies pay providers there.
